Phaseline

Targets › HIV1

HIV1: drug programs, companies and trials

3 programs from 1 company in 3 trials: 3 Phase 1; Infectious disease; next expected readout Dec 2027.

Open in Phaseline: the race on HIV1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
National Institute of Allergy and Infectious Diseases (NIAID)DV201P-RNA
mRNA encoding HIV-1 Env gp150 transmembrane trimers to induce V2 apex-directed broadly neu
HIV1Phase 1HIVDec 2027
National Institute of Allergy and Infectious Diseases (NIAID)DV202B1-RNA
mRNA encoding HIV-1 Env gp150 transmembrane trimers to induce V2 apex-directed broadly neu
HIV1Phase 1HIVDec 2027
National Institute of Allergy and Infectious Diseases (NIAID)Ad4-Env150KN
Adenovirus serotype 4 vector expressing HIV-1 envelope protein
HIV1Phase 1Healthy VolunteerNov 2028

Conditions

HIV (2) Healthy Volunteer (1)

Modalities

protein or peptide (3)

Companies

National Institute of Allergy and Infectious Diseases (NIAID) (3)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.